Ask AI
ProCE Banner Activity

monarchE: Molecular Profiling of Primary Tumor Tissue and ctDNA Detection in Patients With High-Risk, Node-Positive HR+/HER2- EBC Treated With Adjuvant ET ± Abemaciclib

Conference Coverage
Slideset

Analysis of monarchE showed the addition of abemaciclib to adjuvant ET improved invasive disease–free survival in patients with node-positive, high-risk HR-positive/HER2-negative early breast cancer irrespective of molecular subtype, inferred Oncotype-RNA risk score, and across most common genomic alterations while a pilot study found that ctDNA positivity at baseline and 24 months is predictive of recurrence in monarchE participants.

Released: December 10, 2023

Review Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Lilly, Merck Sharp & Dohme LLC, and Seagen Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Lilly

Merck Sharp & Dohme, LLC

Seagen Inc.